Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selecting a medical therapy for overactive bladder.

H Henry Lai, Timothy B Boone, Rodney A Appell

    Reviews in Urology
    |September 21, 2006
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Symptoms and subtypes of patients with lower urinary tract dysfunction - insights from the Symptoms of Lower Urinary Tract Dysfunction Research Network.

    Nature reviews. Urology·2026
    Same author

    Generalized Sensory Sensitivity in Patients With Urinary Urgency-A LURN II Urinary Urgency Phenotyping Study.

    The Journal of urology·2026
    Same author

    The LURN Study-What Have We "LURN"ed So Far?

    Neurourology and urodynamics·2026
    Same author

    Lessons learned from conducting a multi-center lower urinary tract physiology study: the LURN experience.

    Continence (Amsterdam, Netherlands)·2026
    Same author

    Reply by Authors.

    The Journal of urology·2026
    Same author

    Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention.

    Lancet (London, England)·2026
    Same journal

    Erratum: Author's Name Correction for "From Radical to Partial Nephrectomy in the Setting of Solitary Functioning Kidney: Neoadjuvant Treatment of Renal Cell Carcinoma".

    Reviews in urology·2021
    Same journal

    Update in Female Hormonal Therapy: What the Urologist Should Know: NYU Case of the Month, December 2020.

    Reviews in urology·2021
    Same journal

    Genetic Mutations Associated With Prostate Cancer and Normal Serum PSA and DRE-Implications for Prostate Cancer Screening and Management: NYU Case of the Month, November 2020.

    Reviews in urology·2021
    Same journal

    Surgical Management of the "Large" Prostate: The Robotic Simple Prostatectomy: NYU Case of the Month, October 2020.

    Reviews in urology·2021
    Same journal

    Cryptozoospermia Associated With Genital Tucking Behavior in a Transwoman.

    Reviews in urology·2021
    Same journal

    Washington Roundup.

    Reviews in urology·2021
    See all related articles

    Newer formulations of oxybutynin and tolterodine offer improved tolerability over immediate-release oxybutynin for overactive bladder treatment. These advancements lead to better patient compliance and fewer treatment modifications due to side effects.

    Area of Science:

    • Pharmacology
    • Urology
    • Drug Delivery Systems

    Background:

    • Immediate-release oxybutynin was a long-standing treatment for overactive bladder (OAB).
    • Systemic side effects, notably dry mouth, limited its use and patient adherence.
    • Need for improved OAB pharmacotherapies with better tolerability.

    Purpose of the Study:

    • To compare the tolerability of newer OAB oral agents with immediate-release oxybutynin.
    • To evaluate the impact of improved side effect profiles on patient compliance.

    Main Methods:

    • Review of multiple studies comparing different OAB medications.
    • Analysis of patient compliance and dosage adjustment data.
    • Assessment of side effect profiles across various formulations.

    Related Experiment Videos

    Main Results:

    • Extended-release oxybutynin and tolterodine demonstrate superior tolerability compared to immediate-release oxybutynin.
    • Even at higher doses, extended-release oxybutynin showed better tolerability.
    • Improved side effect profiles correlate with increased patient compliance.

    Conclusions:

    • Newer oral agents for overactive bladder offer significant tolerability advantages.
    • Enhanced drug delivery systems and potential bladder selectivity contribute to improved side effect profiles.
    • Better tolerability of extended-release formulations leads to improved patient adherence and treatment outcomes.